
    
      Three active treatment groups and a placebo group are planned. Randomization will be
      sequential by dose level across the sites with placebo assignments randomly inserted. Each
      subject's participation will be approximately 8 months, including screening, treatment
      period, and a 3-month follow-up period.
    
  